

ARAMIS
LAB
BRAIN DATA SCIENCE

Neuroimagerie, neurologie et modèles numériques pour la maladie d'Alzheimer

Stéphane Epelbaum, Stanley Durrleman

www.aramislab.fr

@aramislab


ima institut
de la mémoire
et de la maladie
d'Alzheimer




ICM
Institut du Cerveau
et de la Moelle épinière

UPMC
SORBONNE UNIVERSITÉS


2012




2050





Données Epidémiologiques

- 
- 950 000 personnes touchées en France en 2009 (*Wimo et al, 2010*).
 - La maladie d'Alzheimer est la deuxième cause de handicap en France, et représente 225 000 nouveaux cas par an en France (*Commenges et al, 2004*).
 - Si l'incidence, la durée et le traitement de la maladie ne changent pas:
 - En 2020 : 1 200 000 malades
 - En 2040 : 2 100 000 malades
 - 34,4 Millions
 - Grand cause nationale (2007)
 - 17-20 Millions
 - Plan Alzheimer (2008-2012)
 - Plan Maladies neurodégénératives (2014-2019)

Si l'on retarde le début de la phase symptomatique de la maladie...





Brookheimer et al. *Am J Pub Health*. 1998;88:1337-1342.



(Alzheimer 1906, 1907, Fisher 1907)


Évolution du concept de la maladie d'Alzheimer






Progression de la maladie

Thal




Aβ ↑ →



Braak



Tau ↑ →



(Braak et Braak 1991, Thal et al 2002)

tests cognitifs :
**Pas de pattern
spécifique**

CT or MRI:
proposé pour exclure des
lésions vasculaires,
tumoraes...

**Clinical diagnosis
of Alzheimer's disease:**
**Report of the NINCDS-ADRDA Work Group* under the
auspices of Department of Health and Human Services
Task Force on Alzheimer's Disease**

Guy McKhann, MD; David Drachman, MD; Marshall Folstein, MD; Robert Katzman, MD;
Donald Price, MD; and Emanuel M. Stadlan, MD



1984

LCR:
proposé pour exclure une
méningite

FDG-PET
non mentionné et
PET amyloïde inconnu

Critères révisés IWG-2 de la maladie d'Alzheimer à but de recherche

1. **Un phénotype clinique spécifique:**
 - Syndrome amnésique
2. **Un marqueur d'état physiopathologique de MA:**



Critères NIA AA de la maladie d'Alzheimer (Avril 2018)



ELSEVIER



CrossMark


Alzheimer's & Dementia 14 (2018) 535-562

Alzheimer's
&
Dementia


2018 National Institute on Aging—Alzheimer's Association (NIA-AA) Research Framework


NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease


Clifford R. Jack, Jr.,^{a,*}, David A. Bennett^b, Kaj Blennow^c, Maria C. Carrillo^d, Billy Dunn^e,
Samantha Budd Haeberlein^f, David M. Holtzman^g, William Jagust^h, Frank Jessenⁱ,
Jason Karlawish^j, Enchi Liu^k, Jose Luis Molinuevo^l, Thomas Montine^m, Creighton Phelpsⁿ,
Katherine P. Rankin^o, Christopher C. Rowe^p, Philip Scheltens^q, Eric Siemers^r,
Heather M. Snyder^d, Reisa Sperling^s



En réalité la situation est beaucoup plus complexe...








Build digital model of brain aging from clinical and imaging data

Understand


effects of the disease on the brain
and their heterogeneity at the
individual level

Predict


disease onset



Hierarchical model



Spatiotemporal hierarchical model



- A statistical model to estimate:
 - a **population average trajectory** of data changes
 - **Individual spatiotemporal variations** in:
 - measurement values
 - pace of measurement changes
- Orthogonality condition ensures unique space/time decomposition
- Time is not a covariate but a random variable
- Inference with stochastic optimization methods

Random effects:

Acceleration factor

$$\alpha_i \sim \log \mathcal{N}(0, \sigma_\alpha^2)$$

Time-shift

$$\tau_i \sim \mathcal{N}(0, \sigma_\tau^2)$$

Space-shift

$$v_i = (A_1 | \dots | A_K) s_i$$

$$A_k \perp v_0$$


Fixed effects:

$$(p_0, t_0, v_0)$$

Model of cognitive decline in Alzheimer's Disease

- Neuropsychological tests ADAS-Gog from ADNI
- 248 subjects who converted from MCI to AD
- 6 time-points per subjects on average (min 3, max 11)
- Data points $y_{ij} \in]0, 1[^4$ with propagation logistic model


The average trajectory of data changes



Distinguish **fast** vs. **slow** progressers

Distinguish **early** vs. **late** onset individuals

Variability in the **relative timing** and **ordering** of the events



— memory — language — praxis — concentration

Automatic prognosis system (patent pending)

Parametres

alpha :1.00

tau:0.00

s1:0.00


s2:0.00

Sujet

Numero sujet

Nombre de visites

Reset



Automatic prognosis system (patent pending)

Parametres

alpha :0.93

tau:3.51


s1:-0.41

s2:0.49

Sujet

Numero sujet

Nombre de visites



Automatic prognosis system (patent pending)

Parametres

alpha :0.93

tau:3.51


s1:-0.41

s2:0.49

Sujet

Numero sujet

Nombre de visites



Automatic prognosis system (patent pending)

Parametres

alpha :1.01

tau:3.07


s1:0.06

s2:0.20

Sujet

Numero sujet

Nombre de visites



Automatic prognosis system (patent pending)

Parametres

alpha :1.08

tau:3.23


s1:0.10

s2:-0.26

Sujet

Numero sujet

Nombre de visites



Automatic prognosis system (patent pending)

Parametres

alpha :0.86

tau:2.97


s1:0.11

s2:-0.26

Sujet

Numero sujet

Nombre de visites



Automatic prognosis system (patent pending)

Parametres

alpha :1.09

tau:3.62


s1:-0.26

s2:-0.49

Sujet


Numero sujet

Nombre de visites




Model of cortical atrophy in Alzheimer's Disease

- Maps of cortical thickness
 - 1827 nodes (patches)
 - 258 control nodes
- 248 subjects who converted from MCI to AD
- 6 time-points per subjects on average (min 3, max 11)




Reconstruction of individual observations by model personalization





Reconstruction error at the individual vertex level

(1.5 millions of patches in 787 meshes from 154 individuals)



Model of cortical atrophy in Alzheimer's Disease



APOE e4 carriers have an earlier onset and faster cortical atrophy than others ($p < 0.05$)

63.8y

67.8y

71.8y

75.8y

79.8y

83.8y

87.8y

Time

Morphological variations
1 "spatial" mode

+3 σ


+2 σ

+ σ


- σ

-2 σ


-3 σ



Dynamical model of hippocampal atrophy in Alzheimer's Disease




Female have a faster hippocampal atrophy than male
($p < 0.05$)



APOE carriers have an earlier hippocampal atrophy
than non-carriers ($p < 0.05$)



- A generic Bayesian mixed-effect model for longitudinal data

- Concept of time-warp for temporal variability
- Condition for spatial-temporal identifiability
- Individual effects allow personalization and prediction



- Personalized models of

- cognitive decline
- cortical atrophy
- hippocampal atrophy
- → association with dynamical parameters only?



- Evaluate the predictive power of the model

- Model Personalization to assess predictive power
- Computer-aided diagnosis and prognosis systems